Desvenlafaxine Dosing for Major Depressive Disorder
The recommended dose of desvenlafaxine is 50 mg once daily, which serves as both the starting dose and the therapeutic dose, with no titration required. 1
Standard Dosing Regimen
- Initiate treatment at 50 mg once daily, taken at approximately the same time each day, with or without food 1
- Swallow tablets whole—do not divide, crush, chew, or dissolve 1
- No dose escalation is necessary, as clinical trials demonstrated that doses above 50 mg/day provided no additional benefit while increasing adverse reactions and discontinuation rates 1
- The 50 mg dose achieved response rates of 51-63% and remission rates of 31-45% at 8 weeks in clinical trials 2
Dose Adjustments for Renal Impairment
- Moderate renal impairment (creatinine clearance 30-50 mL/min): Maximum dose 50 mg once daily 1
- Severe renal impairment (creatinine clearance 15-29 mL/min) or end-stage renal disease (creatinine clearance <15 mL/min): Maximum dose 25 mg daily or 50 mg every other day 1
- Do not administer supplemental doses after dialysis 1
Dose Adjustments for Hepatic Impairment
- Moderate to severe hepatic impairment (Child-Pugh score 7-15): Maximum dose 50 mg once daily 1
- Do not escalate above 100 mg/day in patients with hepatic impairment 1
Discontinuation Protocol
- Taper gradually over 10-14 days rather than stopping abruptly to minimize discontinuation symptoms 3, 4
- Use the 25 mg/day dose for gradual tapering when discontinuing treatment 3, 1
- Discontinuation symptoms may include dizziness, fatigue, myalgias, nausea, insomnia, anxiety, and sensory disturbances 5
Switching from Other Antidepressants
- When switching from other antidepressants to desvenlafaxine, taper the initial antidepressant to minimize discontinuation symptoms 1
- Allow at least 14 days after discontinuing an MAOI before starting desvenlafaxine 1
- Allow at least 7 days after stopping desvenlafaxine before starting an MAOI 1
Maintenance Treatment
- Continue treatment for several months or longer after acute episode resolution, as acute episodes of major depressive disorder require sustained pharmacologic therapy 1
- Long-term efficacy at 50 mg/day was demonstrated in maintenance trials, with an estimated 6-month relapse probability of 14.3% versus 30.2% for placebo 6
- Reassess patients periodically to determine the need for continued treatment 1
Key Pharmacokinetic Advantages
- Steady-state plasma concentrations are achieved within 4-5 days of once-daily dosing 1
- Metabolism does not depend on CYP2D6, making it suitable for patients who are CYP2D6 poor or extensive metabolizers 1, 7
- Low potential for drug-drug interactions, as desvenlafaxine does not inhibit or induce major CYP enzymes and is not a substrate for P-glycoprotein 1, 7
Common Pitfalls to Avoid
- Do not escalate above 50 mg/day seeking additional efficacy—higher doses increase adverse events without improving outcomes 1
- Do not abruptly discontinue—always taper gradually to prevent discontinuation syndrome 1
- Monitor blood pressure, as desvenlafaxine can cause sustained hypertension, particularly at higher doses 1
- Screen for suicidal thinking and behavior in patients through age 24 years during treatment 4